These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 23769402)

  • 1. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
    Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of cardiovascular events in Italian patients with early discontinuations of antihypertensive, lipid-lowering, and antidiabetic treatments.
    Corrao G; Zambon A; Parodi A; Merlino L; Mancia G
    Am J Hypertens; 2012 May; 25(5):549-55. PubMed ID: 22278212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and prevention among patients with stroke: a study of 36,844 patients hospitalized in France].
    Tuppin P; Moysan V; de Peretti C; Schnitzler A; Fery-Lemonnier E; Woimant F
    Rev Neurol (Paris); 2013 Feb; 169(2):126-35. PubMed ID: 22749335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006.
    Ahola TL; Kantola IM; Puukka P; Kattainen A; Klaukka T; Reunanen A; Jula AM
    Eur J Cardiovasc Prev Rehabil; 2010 Aug; 17(4):477-85. PubMed ID: 20220527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Reiner Z; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):530-40. PubMed ID: 20577089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003.
    Chiang CW; Chen CY; Chiu HF; Wu HL; Yang CY
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):412-21. PubMed ID: 17252613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal management of cardiovascular risk factors in coronary heart disease patients in primary care occurs particularly in women.
    Driscoll A; Beauchamp A; Lyubomirsky G; Demos L; McNeil J; Tonkin A
    Intern Med J; 2011 Oct; 41(10):730-6. PubMed ID: 21627740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care].
    Scholze J; Lilienthal W; Bramlage P
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():103-10. PubMed ID: 17955787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of a medical aid administrator database for costs and utilisation of benefits by patients claiming for lipid-lowering agents.
    Moodley I
    Cardiovasc J S Afr; 2006; 17(3):140-5. PubMed ID: 16807632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003.
    Chiang CW; Chiu HF; Chen CY; Wu HL; Yang CY
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):62-9. PubMed ID: 17924453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in antidiabetic medication intensity among Medicare beneficiaries with diabetes mellitus.
    Stuart B; Shaffer TJ; Simoni-Wastila LJ; Zuckerman IH; Quinn CC
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):195-208. PubMed ID: 17996659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988-2014.
    Sun X; Du T
    BMC Public Health; 2017 Nov; 17(1):893. PubMed ID: 29166886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of drug usage and expenditure in a hospital diabetes clinic.
    Wu SY; Lung BC; Chang S; Lee SC; Critchley JA; Chan JC
    J Clin Pharm Ther; 1998 Feb; 23(1):49-56. PubMed ID: 9756112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study.
    Devine J; Linton A; Mistry H; Napier J; Trice S; Bacon T
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of drugs related to the treatment of diabetes mellitus and other cardiovascular risk factors in the Spanish population. The Di@bet.es study.
    Rojo-Martínez G; Valdés S; Colomo N; Lucena MI; Gaztambide S; Gomis R; Casamitjana R; Carmena R; Catalá M; Martínez-Larrad MT; Serrano-Ríos M; Castaño L; Vendrell J; Girbés J; Franch J; Vázquez JA; Mora-Peces I; Urrutia I; Pascual-Manich G; Ortega E; Menéndez E; Delgado E; Bordiú E; Castell C; López-Alba A; Goday A; Calle A; Bosch-Comas A; Soriguer F
    Rev Esp Cardiol (Engl Ed); 2013 Nov; 66(11):854-63. PubMed ID: 24773992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.